Table 2 Subgroup analyses of included studies
N | Event, % | 95% CI | ||
|---|---|---|---|---|
FSGS | ||||
Remission | ||||
RTX < 1500 mg/m2 | 2 | 78.5 | 59.7–90.0 | |
RTX ≥ 1500 mg/m2 | 3 | 48.4 | 4.0–99.5 | Q = 0.235, p = 0.628 |
Prior to 2015 | 2 | 31.7 | 1.0–95.6 | |
2015 and later | 3 | 65.3 | 14.7–95.4 | Q = 0.367, p = 0.545 |
Relapse | ||||
RTX < 1500 mg/m2 | 3 | 45.3 | 18.1–75.6 | |
RTX ≥ 1500 mg/m2 | 1 | 57.1 | 23.0–85.6 | Q = 0.220, p = 0.639 |
Prior to 2015 | 2 | 31.8 | 15.0–55.2 | |
2015 and later | 2 | 67.3 | 37.6–87.5 | Q = 3.445, p = 0.063 |
MCD | ||||
Remission | ||||
RTX < 1500 mg/m2 | 6 | 86.5 | 72.0–94.1 | |
RTX ≥ 1500 mg/m2 | 5 | 73.4 | 53.2–87.1 | Q = 1.669; p = 0.196 |
Prior to 2015 | 6 | 81.6 | 70.2–89.3 | |
2015 and later | 5 | 79.7 | 51.8–93.5 | Q = 0.027, p = 0.871 |
Relapse | ||||
RTX < 1500 mg/m2 | 6 | 31.3 | 20.7–44.4 | |
RTX ≥ 1500 mg/m2 | 4 | 41.7 | 22.5–63.8 | Q = 0.687, p = 0.407 |
Prior to 2015 | 6 | 37.3 | 23.4–53.8 | |
2015 and later | 4 | 32.2 | 15.6–55.1 | Q = 0.145, p = 0.703 |